Under the terms of the agreement, Strides will collaborate with Kenox on the development and filing of multiple nasal spray products for the US market across diverse therapeutic indications. Specific product details remain confidential at this stage.
“We are delighted to announce this partnership with Kenox, a company that brings deep technical expertise in the OINDP space. Nasal sprays have consistently been highlighted as a key focus area for Strides, and this collaboration further builds on the solid progress we have already made in this domain. With continued investments in the capabilities and capacities at our US facility, these products are a natural fit within our strategy to expand into our nasal spray technology domain. Kenox’s formulation and development strengths perfectly complement our manufacturing and go-to-market strengths allowing us to accelerate our range of nasal spray offerings in the US market.” said Aditya Kumar, Executive Director Business Development, Strides Pharma Science Limited.
Dr. Sitaram Velaga, Founder, President and CEO of Kenox Pharmaceuticals Inc., added, “Our strategic partnership with Strides is a significant milestone for Kenox. This collaboration validates our expertise in the OINDP space and will allow us to leverage our capabilities to bring important drug products to global patients at an affordable price.”
The partnership will advance a pipeline of
nasal spray products for the US market, combining Strides’ commercial strengths with Kenox’s OINDP expertise to deliver affordable, high-quality therapies to patients.
Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donor- funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on “difficult to manufacture” products sold in over 100 countries.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.